Home » A late-stage drug development company specialized in oncology and endocrine therapy.

A late-stage drug development company specialized in oncology and endocrine therapy.

Neuroblastoma is definitely a malignancy of the nervous program affecting mostly children and infants that there are no FDA authorized therapies. Keryx is definitely Aeterna Zentaris’ partner and licensee for perifosine in the usa, Canada and Mexico. Related StoriesNew antenna-like device makes breast cancer medical procedures less difficult for surgeonsViralytics enters into medical trial collaboration contract with MSDSausages With Antioxidants From Berries TO AVOID CancerJuergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, The orphan-medication designation in neuroblastoma is another essential milestone in the development of perifosine as a novel approach to treating cancer patients, particularly in this area of unmet medical want. We are looking forward to perifosine’s future advancement in neuroblastoma and in other indications with this partner Keryx.A fresh finding in liver transplantation and antifibrinolytics? Orthotopic liver transplantation is connected with heavy bleeding and substantial transfusion requirements. There are many reasons for this heavy bleeding in OLT. Hemostatic abnormalities remain a major cause. This study, performed by a group led by Professor Wang Xuehao, is to be published in the March 7, 2008 issue of the Globe Journal of Gastroenterology. Aprotinin, a serine protease inhibitor, is used increasingly frequently in surgeries during functions such as cardiac surgery and liver transplantation to reduce bleeding and transfusion .We performed a meta-analysis to review the effect of aprotinin found in OLT on the intraoperative requirement of blood products and the postoperative outcomes.